Monday, 26 July 2010

Brazil discusses patentability of medicines

On the 23th of July, the Brazilian Instituto Nacional da Propriedade Industrial (INPI) opened a debate regarding the criteria of patentability in the field of medicines. The meeting was attended by ALANAC (National Association of Pharmaceutical Laboratories), ABIFINA (Brazilian Association of Industries of Fine Chemistry, Biotechnology and their Specialties), FIOCRUZ (Institution for Research and Development in Biomedical Sciences – Rio de Janeiro, Brazil), and UFRJ (Universidade Federal do Rio de Janeiro ). Also, representatives of national laboratories attended the debate.

Let’s wait and see if something comes out from this debate.

2 comments:

Anonymous said...

do you know what the substance of the discussion/debate was?

Patricia Covarrubia said...

The INPI web page only disclosed that the debate was regarding the ‘criteria for patentability'. I cannot elaborate more on that, however my guess – and I will be speculating, is that the discussion could have been in: pipeline system and/or the double examination on the same invention when ANVISA intervenes (this issue has brought contradictory decisions). As soon as we get more in-depth info on this, it will be posted – and if some of our readers know or have more facts, we will like to hear from them.
In general I think that the pharma patent in Brazil has always been controversial and so, any debate and discussion from different sectors is always welcome.